ARCpoint Inc
ARC
Minas Metals Ltd
MINA
Quri-Mayu Developments Ltd
QURI
KGL Resources Ltd
KGL.H
Alerio Gold Corp
ALE
CA Stock MarketDetailed Quotes
RVV Revive Therapeutics Ltd
- 0.005
- -0.005-50.00%
15min DelayMarket Closed Dec 13 10:52 ET
2.09MMarket Cap-0.50P/E (TTM)
0.010High0.005Low102.00KVolume0.010Open0.010Pre Close515.00Turnover0.04052wk High0.03%Turnover Ratio418.56MShares0.00552wk Low-0.01EPS TTM2.06MFloat Cap0.960Historical HighLossP/E (Static)411.61MShs Float0.005Historical Low-0.01EPS LYR50.00%Amplitude--Dividend TTM0.31P/B1Lot Size--Div YieldTTM
Revive Therapeutics Ltd Key Stats
Quarterly+Annual
YOY
| (Q1)Sep 30, 2024 | (FY)Jun 30, 2024 | (Q4)Jun 30, 2024 | (Q3)Mar 31, 2024 | (Q2)Dec 31, 2023 | (Q1)Sep 30, 2023 | (FY)Jun 30, 2023 | (Q4)Jun 30, 2023 | (Q3)Mar 31, 2023 | (Q2)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | 55.13%544.45K | -40.48%3.29M | -34.28%233.33K | -5.31%1.86M | -48.86%783.56K | -79.04%350.96K | -69.04%5.52M | -87.31%355K | -67.50%1.96M | -62.77%1.53M |
| Selling and administrative expenses | 103.01%385.92K | 15.89%2.06M | -33.76%141.52K | 59.43%1.38M | 3.83%278.83K | -55.19%190.1K | -28.84%1.77M | -41.65%213.65K | 196.57%866.92K | -77.69%268.55K |
| -Selling and marketing expense | --23.93K | -78.02%68.93K | ---62.07K | -58.23%131K | ---- | --0 | 3,717.89%313.64K | --0 | 4,609.31%313.64K | ---- |
| -General and administrative expense | 90.42%361.99K | 36.07%1.99M | -4.71%203.59K | 126.14%1.25M | 3.83%278.83K | -55.19%190.1K | -41.23%1.46M | -41.41%213.65K | 93.69%553.28K | -77.69%268.55K |
| Research and development costs | 8.56%144.81K | -69.01%1.11M | -39.87%71.75K | -55.53%471.96K | -65.16%433.22K | -88.49%133.39K | -76.36%3.58M | -94.95%119.32K | -81.41%1.06M | -56.52%1.24M |
| Depreciation amortization depletion | -24.39%62 | -24.42%328 | -24.77%82 | -24.07%82 | -24.77%82 | -24.07%82 | -24.91%434 | -24.83%109 | -25.00%108 | -24.83%109 |
| -Depreciation and amortization | -24.39%62 | -24.42%328 | -24.77%82 | -24.07%82 | -24.77%82 | -24.07%82 | -24.91%434 | -24.83%109 | -25.00%108 | -24.83%109 |
| Other operating expenses | -50.15%13.66K | -26.69%120.22K | -8.86%19.98K | -95.45%1.42K | 251.63%71.42K | -69.73%27.4K | -11.06%163.98K | -67.70%21.92K | 8.49%31.24K | -60.87%20.31K |
| Operating profit | -55.13%-544.45K | 40.48%-3.29M | 34.28%-233.33K | 5.31%-1.86M | 48.86%-783.56K | 79.04%-350.96K | 69.04%-5.52M | 87.31%-355K | 67.50%-1.96M | 62.77%-1.53M |
| Net non-operating interest income (expenses) | -98.13%428 | -40.12%38.69K | -90.52%2.56K | -98.09%297 | 77.20%12.93K | 54.53%22.9K | 22.37%64.61K | 186.07%26.95K | 147.41%15.55K | -57.53%7.3K |
| Non-operating interest income | -95.59%1.39K | -45.05%61.98K | -84.55%5.69K | -80.04%5.3K | -2.51%19.61K | 7.04%31.38K | -8.43%112.79K | 47.94%36.81K | 13.88%26.54K | -43.66%20.12K |
| Non-operating interest expense | -91.55%632 | -54.33%20.1K | -72.35%2.48K | -59.16%4.23K | -49.54%5.9K | -42.34%7.48K | -30.63%44K | -36.85%8.96K | -32.43%10.36K | -28.80%11.7K |
| Total other finance cost | -67.37%325 | -23.52%3.19K | -27.65%654 | 21.71%768 | -30.68%775 | -34.56%996 | -39.84%4.18K | -29.10%904 | -62.57%631 | -46.40%1.12K |
| Other net income (expenses) | 214.30%71.51K | -174.29%-2.37M | -2.35M | -16.62K | -62.57K | -3,137.71%-864.5K | ||||
| Gain on sale of security | 214.30%71.51K | 267.18%146.28K | --182.9K | ---36.62K | ---- | ---62.57K | ---87.5K | ---- | ---- | ---- |
| Special income (charges) | ---- | -224.01%-2.52M | -226.58%-2.54M | --20K | ---- | ---- | -2,810.00%-777K | ---777K | --0 | ---- |
| -Less:Impairment of capital assets | ---- | 201.75%2.34M | ---- | ---- | ---- | ---- | --777K | ---- | ---- | ---- |
| -Less:Other special charges | ---- | ---20K | --0 | ---20K | ---- | ---- | ---- | ---- | ---- | ---- |
| -Gain on sale of business | ---- | ---192.95K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
| Income before tax | -20.96%-472.51K | 11.11%-5.62M | -116.80%-2.59M | 3.71%-1.87M | 49.47%-770.62K | 76.46%-390.62K | 64.50%-6.32M | 57.64%-1.19M | 67.72%-1.94M | 62.79%-1.52M |
| Income tax | ||||||||||
| Earnings from equity interest net of tax | ||||||||||
| Net income | -20.96%-472.51K | 11.11%-5.62M | -116.80%-2.59M | 3.71%-1.87M | 49.47%-770.62K | 76.46%-390.62K | 64.50%-6.32M | 57.64%-1.19M | 67.72%-1.94M | 62.79%-1.52M |
| Net income continuous operations | -20.96%-472.51K | 11.11%-5.62M | -116.80%-2.59M | 3.71%-1.87M | 49.47%-770.62K | 76.46%-390.62K | 64.50%-6.32M | 57.64%-1.19M | 67.72%-1.94M | 62.79%-1.52M |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | -20.96%-472.51K | 11.11%-5.62M | -116.80%-2.59M | 3.71%-1.87M | 49.47%-770.62K | 76.46%-390.62K | 64.50%-6.32M | 57.64%-1.19M | 67.72%-1.94M | 62.79%-1.52M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | -20.96%-472.51K | 11.11%-5.62M | -116.80%-2.59M | 3.71%-1.87M | 49.47%-770.62K | 76.46%-390.62K | 64.50%-6.32M | 57.64%-1.19M | 67.72%-1.94M | 62.79%-1.52M |
| Diluted earnings per share | -3.39%-0.0011 | 50.00%-0.01 | 0 | 17.86%-0.0048 | 54.11%-0.0022 | 89.08%-0.0011 | 66.67%-0.02 | 0.00%-0.01 | 70.66%-0.0059 | 53.06%-0.0047 |
| Basic earnings per share | -3.39%-0.0011 | 50.00%-0.01 | 0 | 17.86%-0.0048 | 54.11%-0.0022 | 89.08%-0.0011 | 66.67%-0.02 | 0.00%-0.01 | 70.66%-0.0059 | 53.06%-0.0047 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.